SomaLogic

Founded in 2000, SomaLogic's mission is to decode the human proteome to revolutionize life sciences and healthcare. Its core achievement is the SomaScan Platform, which leverages proprietary SOMAmer® reagents and KREX™ technology to deliver unparalleled scale, sensitivity, and reproducibility in protein measurement. The company's strategy focuses on providing fee-for-service assay services globally, expanding its menu of SomaSignal diagnostic tests, and leveraging its 2024 merger with Standard BioTools to accelerate leadership in integrated multi-omics solutions.

The SomaScan Platform uses proprietary SOMAmer® DNA aptamers and KREX™ kinetic exclusion technology to enable high-throughput, multiplexed measurement of up to 11,000 proteins from a single 55µL sample of blood plasma or serum with exceptional sensitivity, specificity, and reproducibility.